Skin Cancer

Conference Insider

Cosibelimab Safe, Clinically Active in Patients With mCSCC

09/19/2020

Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.

Preliminary safety and efficacy...

09/19/2020

Oncology

Videos

Experts Seek to Establish Adjuvant Role of Cemiplimab in Treatment of CSCC

06/05/2020

Danny Rischin, MBBS, FRACP, MD, discusses the clinical importance of a phase 3 clinical trial evaluating adjuvant cemiplimab in patients with high-risk CSCC.

Danny Rischin, MBBS, FRACP, MD,...

06/05/2020

Oncology

Videos

Few Side Effects With Intrathecal vs Systemic Nivolumab for Metastatic Melanoma and Brain Tumors

06/01/2020

Claire Verschraegen, MD, discusses a study of toxicities associated with the use of intrathecally-injected nivolumab in patients with metastatic melanoma who have leptomeningeal disease.

Claire Verschraegen, MD,...

06/01/2020

Oncology

Videos

Cemiplimab Yields High Rate of Durable Responses in Advanced CSCC

05/31/2020

Danny Rischin, MBBS, FRACP, MD, discusses a phase 2 clinical trial in which cemiplimab was shown to yield high rates of long-term response in patients with advanced CSCC.

Danny Rischin, MBBS, FRACP, MD,...

05/31/2020

Oncology

News

Nivolumab Plus Ipilimumab Extends TFS Over Nivolumab Alone in Advanced Melanoma

05/31/2020

With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a TFS twice as long as those given nivolumab alone.

With extended follow-up,...

05/31/2020

Oncology